Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954310 | 0.95 | CRBN (0.48) | DDB1CRBNKDM4EALDH1A1HPGD | |
| SCHEMBL19953924 | 0.95 | CRBN (0.48) | DDB1CRBNKDM4EALDH1A1HPGD | |
| SCHEMBL19953921 | 0.95 | CRBN (0.48) | DDB1CRBNKDM4EALDH1A1HPGD | |
| SCHEMBL23979589 | 0.94 | DDB1 (0.43) | DDB1CRBNKDM4EALDH1A1HPGD | |
| SCHEMBL23979425 | 0.92 | DDB1 (0.45) | DDB1CRBNKDM4EALDH1A1NR1H2 | |
| SCHEMBL23979421 | 0.91 | DDB1 (0.43) | DDB1CRBNKDM4EALDH1A1NR1H2 | |
| SCHEMBL23979497 | 0.91 | DDB1 (0.46) | DDB1CRBNKDM4EALDH1A1NR1H2 | |
| SCHEMBL26360653 | 0.90 | DDB1 (0.44) | DDB1CRBNKDM4EALDH1A1NR1H2 | |
| SCHEMBL23979592 | 0.90 | DDB1 (0.44) | DDB1CRBNALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19953919 | 0.89 | DDB1 (0.47) | DDB1CRBNKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | SALARIUS PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | HPGDS, HPGD, AQP3 | DDB1 690/4885CRBN 1079/4885KDM4E 732/4885 |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | HPGDS, HPGD, AQP3 | DDB1 690/4885CRBN 1079/4885KDM4E 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.